Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?

about

Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?

Item

http://www.wikidata.org/entity/Q52660416

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@en

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@nl

type

Item

label

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@en

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@nl

prefLabel

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@en

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@nl

P1476

Disrupting Virchow's triad: ca ...... with ischaemic cardiomyopathy?

@en

P2093

Tariq Ahmad

http://www.w3.org/2001/XMLSchema#string

P2860

Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm

The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure

Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Clinical implications of chronic heart failure phenotypes defined by cluster analysis.

Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Virchow and his triad: a question of attribution.

Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.

Warfarin and aspirin in patients with heart failure and sinus rhythm.

P304

647-651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/EJHF.296

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Javed Butler

P577

2015-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26018996

http://www.w3.org/2001/XMLSchema#string